Ex vivo animal or challenge model as method to measure protective immunity directed against parasites and vaccines shown to be protective in said method

A process for producing a vaccine, said process comprising:

• incorporating a protein and a pharmaceutically suitable carrier into a vaccine composition, said protein comprising the N-terminal amino acid sequence set forth in SEQ ID NO 1.

A process of producing a vaccine directed against an infection caused by a Fasciola hepatica, said process comprising:

• selecting a protective protein comprising an amino acid sequence from a pro-region of a cathepsin L protease obtained from excretory/secretory products of newly excysted juvenile stages of Fasciola hepatica,
• recombinantly expressing said protective protein, and
• incorporating said recombinantly expressed protective protein and a pharmaceutically suitable carrier into a vaccine composition.

A process of producing a vaccine comprising:

• providing an amino acid sequence comprising a pro-sequence of a cathepsin L protease obtained from excretory/secretory products of a newly excysted juvenile stage Fasciola hepatica;
• and
• incorporating the amino acid sequence and a pharmaceutically suitable carrier into a vaccine composition.